Annovis Provides Corporate Updates and Reports First Quarter 2026 Financial Results
Annovis reported Q1 2026 results with a net loss of $17.6 million and EPS of -$0.63, driven by a surge in R&D expenses to $16.7 million from $5.0 million year-over-year. Cash and cash equivalents stood at $14.2 million as of March 31, excluding $10 million in proceeds from a registered direct offering completed in April 2026. Clinically, the pivotal Phase 3 Alzheimer’s trial reached 85% enrollment, with full enrollment expected in summer 2026 and top-line symptomatic data anticipated in early 2027.
Key figures
- Revenue
- 0
- Ga expenses
- 1291820
- Rd expenses
- 16720362
- Shares outstanding
- 28537302
- Cash and equivalents
- 14219081
- Pd ole enrollment pct
- 40%
- Ad trial enrollment pct
- 85%
AI analysis
Red flags3 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.